UCB certolizumab Crohn’s data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
UCB's Cimzia (certolizumab pegol, CDP870) showed positive efficacy results in the pivotal PRECISE 1 and 2 trials, the company says July 26. The trials are looking at certolizumab in induction and maintenance of clinical response in moderate to severe active Crohn's disease over 26 weeks. UCB plans to present the data "in more detail at the major forthcoming gastroenterology medical congresses." Cimzia also is in Phase III studies for rheumatoid arthritis...